Illustrative image.

Mounjaro

Name: Mounjaro
Brand: Eli lilly
Availability: InStock

Tirzepatide

Prescription required

$2100.00

2.5 mg · 3 × 1 pre-filled pen · 3 months supply

BrandBranded medicine· By Eli lilly

$700.00 per month

Strength

How long a supply?

1 month$700.00 a monthOne-off$700.00

3 months$700.00 a monthOne-off$2100.00

Supplied from Canada

Test mode: no payment is taken. View cart

Annual cost

$9100a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

2.5 mg

5 mg

7.5 mg

10 mg

12.5 mg

15 mg

FDA boxed warningRisk of thyroid c-cell tumors

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined

MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Read this with the rest of the clinical information

About Mounjaro

Overview

Mounjaro contains tirzepatide and is given as an injection under the skin. It is used alongside diet and exercise to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It is also used to reduce the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who are at high risk of these events. It activates GIP and GLP-1 receptors, helping the body release insulin and reduce glucagon, a hormone that raises blood sugar, in response to blood sugar levels.

What it treats

- To improve blood sugar control alongside diet and exercise in adults and children aged 10 years and older with type 2 diabetes. - To reduce the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with type 2 diabetes who are at high risk of these events.

Safety information

Side effects

Common side effects of Mounjaro (tirzepatide) include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain. Each was reported in at least 5% of treated patients. Serious risks include inflammation of the pancreas (acute pancreatitis), severe allergic reactions, kidney injury due to fluid loss, severe digestive problems, gallbladder disease and worsening diabetes-related eye disease in people who already have it. Low blood sugar, including severe episodes, can occur when Mounjaro is used with insulin or medicines that stimulate insulin release. The label also warns about the risk of thyroid C-cell tumors. Contact a doctor promptly if a serious side effect is suspected. Stop using Mounjaro if pancreatitis or a serious allergic reaction is suspected, and seek medical advice promptly. Serious allergic reactions reported include anaphylaxis and angioedema. Inhalation of stomach contents into the lungs during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists. Tell your healthcare providers about Mounjaro use and any planned surgery or procedure.

FDA boxed warning

Risk of thyroid c-cell tumors

MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention for trouble breathing or swallowing. - Contact your doctor promptly for a lump in your neck or hoarseness that does not go away. - Seek immediate medical attention for severe stomach pain, vomiting or diarrhea.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use Mounjaro if you or anyone in your family has had medullary thyroid carcinoma (MTC), if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to tirzepatide or any other ingredient in Mounjaro. Mounjaro is not recommended for people with severe gastroparesis. Other stomach and bowel reactions can occur and may be severe. Reactions that cause fluid loss can lead to acute kidney injury and may require kidney function monitoring. Stop using Mounjaro if pancreatitis or a serious allergic reaction is suspected. Seek medical advice promptly for a suspected serious allergic reaction. Using Mounjaro with insulin or medicines that stimulate insulin release increases the risk of low blood sugar, including severe episodes. Your prescriber may need to adjust those medicines. If you have a history of diabetic retinopathy, you should be monitored for worsening eye disease. Gallbladder disease can occur; suspected gallstones require assessment and follow-up. Tell your healthcare team about any planned surgery or procedure. Inhalation of stomach contents into the lungs has been reported during general anesthesia or deep sedation in people receiving GLP-1 receptor agonists. Mounjaro may harm an unborn baby, based on animal studies. If you use an oral contraceptive, switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. Never share a Mounjaro KwikPen with another person, even if the needle is changed.

Interactions

Mounjaro slows stomach emptying, which may affect how medicines taken by mouth are absorbed. Tell your doctor about any oral medicines you take.

Using Mounjaro

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use and how long it may be kept at room temperature afterwards. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label MOUNJARO (TIRZEPATIDE) INJECTION, SOLUTION MOUNJARO KWIKPEN (TIRZEPATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.